NASDAQ:SYBX - Synlogic Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$11.50 +0.30 (+2.68 %)
(As of 07/16/2018 02:51 AM ET)
Previous Close$11.50
Today's Range$11.1254 - $11.68
52-Week Range$8.73 - $23.00
Volume129,460 shs
Average Volume202,493 shs
Market Capitalization$292.68 million
P/E RatioN/A
Dividend YieldN/A
Beta1.81
Synlogic logoSynlogic, Inc. a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy, which is in Phase I clinical trial for the treatment of patients with liver disease and hepatic encephalopathy, and urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria. The company is also involved in developing discovery-stage product candidates for inborn errors of metabolism, including maple syrup urine disease, isovaleric acidemia, and organic acidemias. It has a collaboration agreement with AbbVie S.à.r.l. to develop synthetic biotic medicines for the treatment of inflammatory bowel diseases; Ginkgo Bioworks to discover new living medicines to treat neurological and liver disorders. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.

Receive SYBX News and Ratings via Email

Sign-up to receive the latest news and ratings for SYBX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SYBX
CUSIPN/A
Phone617-401-9975

Debt

Debt-to-Equity RatioN/A
Current Ratio18.24
Quick Ratio18.24

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.44 million
Price / Sales119.95
Cash FlowN/A
Price / CashN/A
Book Value$3.97 per share
Price / Book2.90

Profitability

EPS (Most Recent Fiscal Year)($5.88)
Net Income$-40,370,000.00
Net MarginsN/A
Return on Equity-49.62%
Return on Assets-44.73%

Miscellaneous

Employees63
Outstanding Shares25,450,000
Market Cap$292.68

The Truth About Cryptocurrencies

Synlogic (NASDAQ:SYBX) Frequently Asked Questions

What is Synlogic's stock symbol?

Synlogic trades on the NASDAQ under the ticker symbol "SYBX."

When did Synlogic's stock split? How did Synlogic's stock split work?

Shares of Synlogic reverse split on the morning of Monday, August 28th 2017. The 1-7 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 25th 2017. An investor that had 100 shares of Synlogic stock prior to the reverse split would have 14 shares after the split.

How were Synlogic's earnings last quarter?

Synlogic Inc (NASDAQ:SYBX) announced its quarterly earnings data on Tuesday, May, 15th. The biotechnology company reported ($0.55) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.73) by $0.18. The biotechnology company had revenue of $0.35 million for the quarter, compared to analyst estimates of $0.21 million. View Synlogic's Earnings History.

When is Synlogic's next earnings date?

Synlogic is scheduled to release their next quarterly earnings announcement on Wednesday, August, 15th 2018. View Earnings Estimates for Synlogic.

What price target have analysts set for SYBX?

5 analysts have issued 1 year price targets for Synlogic's stock. Their predictions range from $15.00 to $25.00. On average, they expect Synlogic's stock price to reach $19.60 in the next year. This suggests a possible upside of 70.4% from the stock's current price. View Analyst Ratings for Synlogic.

What is the consensus analysts' recommendation for Synlogic?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synlogic in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about Synlogic stock?

Here are some recent quotes from research analysts about Synlogic stock:
  • 1. HC Wainwright analysts commented, "We reiterate our Buy rating and $20 12-month target on SYBX." (6/11/2018)
  • 2. According to Zacks Investment Research, "Synlogic, Inc. engaged in the development of a novel class of living Synthetic Biotic(TM) medicines based on its proprietary drug discovery and development platform. The company's pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases such as Urea Cycle Disorder and Phenylketonuria. In addition, the company is leveraging the broad potential of its platform to create Synthetic Biotic medicines for the treatment of other diseases, such as liver disease, inflammatory and immune disorders and cancer. It is collaborating with AbbVie to develop Synthetic Biotic-based treatments for inflammatory bowel disease. Synlogic Inc., formerly known as Mirna Therapeutics Inc., is based in Cambridge, Massachusetts. " (5/22/2018)

Are investors shorting Synlogic?

Synlogic saw a increase in short interest during the month of June. As of June 29th, there was short interest totalling 1,558,261 shares, an increase of 120.1% from the June 15th total of 708,076 shares. Based on an average daily trading volume, of 302,181 shares, the days-to-cover ratio is presently 5.2 days. Currently, 9.8% of the shares of the stock are short sold. View Synlogic's Current Options Chain.

Who are some of Synlogic's key competitors?

Who are Synlogic's key executives?

Synlogic's management team includes the folowing people:
  • Dr. Peter Barrett, Exec. Chairman (Age 65)
  • Dr. Aoife M. Brennan MB, BCh, BAO, MMSc, Interim Pres, CEO & Chief Medical Officer (Age 43)
  • Mr. Paul Francis Miller Ph.D., Chief Scientific Officer (Age 58)
  • Dr. José Carlos Gutierrez-Ramos, Advisor (Age 56)
  • Prof. Timothy K. Lu, Co-Founder

Has Synlogic been receiving favorable news coverage?

News articles about SYBX stock have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Synlogic earned a daily sentiment score of 0.05 on Accern's scale. They also gave press coverage about the biotechnology company an impact score of 44.47 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

How do I buy shares of Synlogic?

Shares of SYBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Synlogic's stock price today?

One share of SYBX stock can currently be purchased for approximately $11.50.

How big of a company is Synlogic?

Synlogic has a market capitalization of $292.68 million and generates $2.44 million in revenue each year. The biotechnology company earns $-40,370,000.00 in net income (profit) each year or ($5.88) on an earnings per share basis. Synlogic employs 63 workers across the globe.

How can I contact Synlogic?

Synlogic's mailing address is 301 Binney St. Suite 402, Cambridge MA, 02142. The biotechnology company can be reached via phone at 617-401-9975 or via email at [email protected]


MarketBeat Community Rating for Synlogic (NASDAQ SYBX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  125 (Vote Outperform)
Underperform Votes:  123 (Vote Underperform)
Total Votes:  248
MarketBeat's community ratings are surveys of what our community members think about Synlogic and other stocks. Vote "Outperform" if you believe SYBX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYBX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.